Patient Enrollment Has Accelerated with Now 10 Patients Enrolled in Phase 2 Trial 6 out of 6 Patients Who Completed the 12-Week Treatment Have Chosen to Remain on TFF TAC by Proceeding to the Safety Extension Phase; 1 patient has been treated for over a year and 3 additional patients have been treated for more than 6 months Variability in Systemic Exposure to Tacrolimus Was Reduced with TFF TAC Which Could Lower Risk of Acute Rejection and Systemic Toxicities FORT WORTH, Texas, May 15, 2024 (GLO
TFF Pharmaceuticals (TFFP) delivered earnings and revenue surprises of -9.09% and 35.33%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Growing Body of Clinical Data from Ongoing Phase 2 Trial Suggests that Tacrolimus Inhalation Powder (TFF TAC) Could Represent an Important New Innovation for Optimizing Immunosuppressive Therapy in Lung Transplant Recipients Raised $6.0 Million to Support Continued Advancement of TFF TAC into Potentially Registrational Testing Company expects to receive feedback from FDA in Second Quarter Regarding TFF TAC Clinical Development Plan and Next Steps FORT WORTH, Texas, May 14, 2024 (GLOBE NEWSWIRE)